De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Itafos Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Itafos heeft een totaal eigen vermogen van $300.0M en een totale schuld van $66.5M, wat de schuld-eigenvermogensverhouding op 22.2% brengt. De totale activa en totale passiva bedragen respectievelijk $604.2M en $304.2M. De EBIT Itafos is $87.0M waardoor de rentedekking 8.7 is. Het heeft contanten en kortetermijnbeleggingen van $59.1M.

Belangrijke informatie

22.2%

Verhouding schuld/eigen vermogen

US$66.55m

Schuld

Rente dekkingsratio	8.7x
Contant	US$59.11m
Aandelen	US$299.96m
Totaal verplichtingen	US$304.24m
Totaal activa	US$604.20m

Recente financiële gezondheidsupdates

Recent updates

Itafos' (CVE:IFOS) Soft Earnings Are Actually Better Than They Appear

Mar 29

Little Excitement Around Itafos Inc.'s (CVE:IFOS) Earnings

Nov 10

Itafos (CVE:IFOS) Knows How To Allocate Capital Effectively

Sep 16

Does Itafos (CVE:IFOS) Have A Healthy Balance Sheet?

Aug 02

Is Itafos (CVE:IFOS) Using Too Much Debt?

Feb 03

Is Itafos (CVE:IFOS) Using Too Much Debt?

Sep 08

These 4 Measures Indicate That Itafos (CVE:IFOS) Is Using Debt Extensively

May 11

Health Check: How Prudently Does Itafos (CVE:IFOS) Use Debt?

Aug 25

Is Itafos (CVE:IFOS) Using Debt In A Risky Way?

Apr 12

This Analyst Just Made A Massive Upgrade To Their Itafos (CVE:IFOS) Earnings Forecasts

Feb 18

Can You Imagine How Elated Itafos' (CVE:IFOS) Shareholders Feel About Its 743% Share Price Gain?

Dec 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $206.5M ) IFOS } overtreffen de korte termijn passiva ( $111.2M ).

Langlopende schulden: De kortetermijnactiva IFOS ( $206.5M ) overtreffen de langetermijnschulden ( $193.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 2.5% ) IFOS wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van IFOS is de afgelopen 5 jaar gedaald van 73.4% naar 22.2%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende IFOS voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: IFOS is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 51.1 % per jaar groeit.

Itafos Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Itafos (CVE:IFOS) Have A Healthy Balance Sheet?

Is Itafos (CVE:IFOS) Using Too Much Debt?

Is Itafos (CVE:IFOS) Using Too Much Debt?

These 4 Measures Indicate That Itafos (CVE:IFOS) Is Using Debt Extensively

Health Check: How Prudently Does Itafos (CVE:IFOS) Use Debt?

Is Itafos (CVE:IFOS) Using Debt In A Risky Way?

Recent updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Itafos Inc. Maintains Operating Guidance for the Year 2024

Niobium Dragon Pty Ltd entered into a binding Share Sale Agreement to acquire Itafos Arraias Mineração e Fertilizantes S.A. from Itafos Inc. (TSXV:IFOS) ) for $14.9 million.

Itafos Inc. Announces Elena Viyella De Paliza Did Not Stand for Re-Election as Director

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Itafos Inc. Announces Results of Updated Itafos Conda Technical Report

Itafos Inc., Annual General Meeting, Jun 19, 2024

Itafos' (CVE:IFOS) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Director exercised options to buy CA$84k worth of stock.

Third quarter 2023 earnings released: EPS: US$0.016 (vs US$0.043 in 3Q 2022)

Itafos Inc. Narrows its Earnings Guidance for 2023

Little Excitement Around Itafos Inc.'s (CVE:IFOS) Earnings

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Itafos (CVE:IFOS) Knows How To Allocate Capital Effectively

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Itafos Inc. Provides Earnings Guidance for the Year 2023

Does Itafos (CVE:IFOS) Have A Healthy Balance Sheet?

Itafos Files Updated Feasibility Study for the Farim Phosphate Project

Itafos Inc. Completes Updated Feasibility Study for the Farim Phosphate Project

Consensus EPS estimates increase by 16%

Itafos Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: EPS: US$0.15 (vs US$0.18 in 1Q 2022)

Itafos Announces Notice to Proceed for Husky 1/North Dry Ridge

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

Is Itafos (CVE:IFOS) Using Too Much Debt?

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 26%

Price target decreased to CA$5.25

Itafos Inc. Provides Earnings Guidance for Fiscal Year 2022

Price target decreased to CA$5.25

Investor sentiment deteriorated over the past week

Is Itafos (CVE:IFOS) Using Too Much Debt?

Investor sentiment improved over the past week

Consensus EPS estimates increase by 17%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Itafos Inc. Appoints Matthew O’Neill as Chief Financial Officer Succeeding George Burdette

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Itafos Inc. Announces Production and Sales of Hydrofluorosilicic Acid at Conda

Investor sentiment improved over the past week

Itafos Inc. Provides Earnings Guidance for the First Half and Second Half of 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Itafos (CVE:IFOS) Is Using Debt Extensively

Less than half of directors are independent

Itafos Inc., Annual General Meeting, Jun 24, 2022

Itafos Inc. Announces Board Changes

Itafos Inc. Announces Resumption of Sulfuric Acid Production at Arraias

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.11 loss in 2Q 2020)

Health Check: How Prudently Does Itafos (CVE:IFOS) Use Debt?

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.10 loss in 1Q 2020)

Is Itafos (CVE:IFOS) Using Debt In A Risky Way?

Full year 2020 earnings released: US$0.34 loss per share (vs US$1.02 loss in FY 2019)

This Analyst Just Made A Massive Upgrade To Their Itafos (CVE:IFOS) Earnings Forecasts

Itafos Appoints David Brush as Chief Strategy Officer

Itafos(TSXV:IFOS) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.52

Itafos Announces Notice of Intent for Conda Mine Life Extension

Can You Imagine How Elated Itafos' (CVE:IFOS) Shareholders Feel About Its 743% Share Price Gain?

Itafos Announces Executive Changes